<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005900</url>
  </required_header>
  <id_info>
    <org_study_id>199/15111</org_study_id>
    <secondary_id>UMN-MT-1999-18</secondary_id>
    <secondary_id>UMN-MT-9818</secondary_id>
    <nct_id>NCT00005900</nct_id>
  </id_info>
  <brief_title>Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fairview University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate bronchoalveolar lavage fluid and serum obtained from pediatric
      patients with storage disorders prior to allogeneic hematopoietic stem cell transplantation
      (HSCT) for the presence of proinflammatory cytokines and for the production of nitric oxide
      by alveolar macrophages to identify possible risk factors for pulmonary complications.

      II. Investigate the underlying mechanism for the development of significant pulmonary
      complications in these patients during HSCT.

      III. Evaluate bronchoalveolar lavage fluid and serum obtained from these same patients at the
      time a pulmonary complication develops post-HSCT, or at 60 days post-HSCT if there has been
      no pulmonary complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:

      Patients undergo bronchoscopy with bronchoalveolar lavage (BAL) prior to allogeneic
      hematopoietic stem cell transplantation (HSCT). ELISA assays for cytokines are performed.
      Patients are followed post-HSCT for the development of transplant related pulmonary
      complications. A repeat bronchoscopy with BAL is performed at the time pulmonary
      complications develop or at day 60 post-HSCT if no complications develop. Cytokine assays are
      repeated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 1999</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
  </study_design_info>
  <enrollment>10</enrollment>
  <condition>I Cell Disease</condition>
  <condition>Fucosidosis</condition>
  <condition>Globoid Cell Leukodystrophy</condition>
  <condition>Adrenoleukodystrophy</condition>
  <condition>Mannosidosis</condition>
  <condition>Niemann-Pick Disease</condition>
  <condition>Pulmonary Complications</condition>
  <condition>Mucopolysaccharidosis I</condition>
  <condition>Mucopolysaccharidosis VI</condition>
  <condition>Metachromatic Leukodystrophy</condition>
  <condition>Gaucher's Disease</condition>
  <condition>Wolman Disease</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  Diagnosis of an inborn error of metabolism eligible for allogeneic hematopoietic stem
             cell transplantation on protocol UMN-MT-1995-01
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K. Scott Baker</last_name>
    <role>Study Chair</role>
    <affiliation>Fairview University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fairview University Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>June 2, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Gaucher's disease</keyword>
  <keyword>I cell disease</keyword>
  <keyword>Niemann-Pick disease</keyword>
  <keyword>Wolman disease</keyword>
  <keyword>adrenoleukodystrophy</keyword>
  <keyword>disease-related problem/condition</keyword>
  <keyword>fucosidosis</keyword>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>globoid cell leukodystrophy</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>mannosidosis</keyword>
  <keyword>metachromatic leukodystrophy</keyword>
  <keyword>mucopolysaccharidosis</keyword>
  <keyword>mucopolysaccharidosis I</keyword>
  <keyword>mucopolysaccharidosis VI</keyword>
  <keyword>oncologic disorders</keyword>
  <keyword>pulmonary complications</keyword>
  <keyword>rare disease</keyword>
  <keyword>sphingolipidoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Gaucher Disease</mesh_term>
    <mesh_term>Adrenoleukodystrophy</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Mannosidase Deficiency Diseases</mesh_term>
    <mesh_term>alpha-Mannosidosis</mesh_term>
    <mesh_term>Wolman Disease</mesh_term>
    <mesh_term>Leukodystrophy, Globoid Cell</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
    <mesh_term>Fucosidosis</mesh_term>
    <mesh_term>Mucolipidoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

